Octave Bioscience, a precision care innovator that is revolutionizing the standard of care for people with multiple sclerosis (MS) and other neurodegenerative diseases, today announced the closing of a $30M extension to its Series B funding round.
New strategic investors including Novartis (dRx Capital), Hikma Pharmaceuticals’ venture capital arm Hikma Ventures, and Intermountain Ventures joined existing investors such as The Blue Venture Fund, Echo Health Ventures, Section 32, Northpond Ventures, Deerfield Management, Casdin Capital, and Merck Global Health Innovation Fund in providing this investment, which will be used to further accelerate the commercialization process and bring Octave’s groundbreaking multimodal solution to MS patients around the world.
Octave is thrilled to have an amazing range of top-tier investors join them in providing a cutting-edge multimodal precision care solution that will enable personalized care, informed treatment decisions, and improved patient outcomes.
Octave has made huge strides in deploying their solution for multiple sclerosis patients, and they are incredibly grateful for the forward-thinking investors who recognize and value their strategy and mission. This investment will help Octave continue to grow and better serve patients everywhere.
Octave is transforming precision healthcare through its complete care solution for people living with multiple sclerosis (MS). Combining powerful blood biomarkers, advanced imaging capabilities and clinical insights, Octave empowers healthcare providers, payers, pharmaceutical companies and, most importantly, patients, with the data needed to more effectively monitor and manage their condition.
Launched in late 2022, Octave paves the way for better healthcare outcomes in MS centers of excellence, academic centers, and high-volume independent clinics. Expanding the scope of its work, Octave is also committed to partnering with pharmaceutical companies and health plans, and building collaborations to revolutionize healthcare for patients living with neurodegenerative diseases like Parkinson’s and Alzheimer’s.
We are astonished by Octave’s all-in-one solution and its capacity to tackle the great unmet need for patients suffering from neurodegenerative diseases. By providing a comprehensive solution that optimizes and personalizes care, Octave is changing the way MS is managed and treated. We are more than excited to fuel their indispensable mission as they continue to make immense strides in MS.
Intermountain Ventures is proud to invest in Octave, a pioneering healthcare solution for those affected by multiple sclerosis. MS is a complex disorder with distinct needs across individuals, yet current diagnosis and treatment methods leave much to be desired in providing the level of personalized care needed. Octave’s precision care offers incredible hope to the millions of Americans living with this condition, and Intermountain Ventures is committed to ensuring its success.
Octave is a revolutionary solution for improving patient care in neurodegenerative diseases, and the alignment of strategic investors from across the ecosystem speaks volumes for its potential. These investors encompass multiple areas of expertise, and their unified support is a powerful endorsement for the promise of Octave.
About Octave Bioscience
Octave Bioscience is revolutionizing healthcare with its innovative Precision Care Solution for multiple sclerosis and other neurodegenerative diseases. Our platform is the first of its kind to combine multiple biological and contextual layers of data, enabling better management of complex diseases and providing clinicians, patients, payers, and pharma companies with the objective insight and longitudinal perspectives needed to usher in a new era of personalized medicine.
Our multivariate blood test, enhanced MRI analytics and protocols, and care program featuring real-time connectivity to MS nurse practitioners will usher in a new paradigm of care for the patients and communities that need it most.